Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 1,144 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 1,144 shares of Cue Biopharma stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.05, for a total transaction of $32,089.20. Following the completion of the transaction, the vice president directly owned 47,817 shares in the company, valued at approximately $1,341,266.85. This represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Vincent Meluzio also recently made the following trade(s):

• On Thursday, August 13th, Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock. The stock was sold at an average price of $30.09, for a total transaction of $169,346.52.

Cue Biopharma Trading Down 5.0%

NASDAQ CUE opened at $18.60 on Thursday. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50. The company has a fifty day simple moving average of $27.73 and a 200 day simple moving average of $72.25. The company has a market cap of $135.11 million, a P/E ratio of -0.69 and a beta of 2.62.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%. Equities research analysts forecast that Cue Biopharma, Inc. will post -21.79 EPS for the current fiscal year.

Institutional Trading of Cue Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC increased its holdings in shares of Cue Biopharma by 301.8% during the 2nd quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock worth $809,000 after purchasing an additional 38,333 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Cue Biopharma during the second quarter valued at about $338,000. Bank of America Corp DE bought a new stake in shares of Cue Biopharma in the second quarter valued at about $219,000. ADAR1 Capital Management LLC bought a new stake in shares of Cue Biopharma in the second quarter valued at about $1,742,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in shares of Cue Biopharma in the second quarter valued at about $83,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CUE shares. Wall Street Zen downgraded Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Zacks Research raised Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. B. Riley Financial began coverage on Cue Biopharma in a research report on Friday, September 18th. They set a “buy” rating and a $83.00 price objective for the company. Finally, Weiss Ratings downgraded Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cue Biopharma has a consensus rating of “Hold” and an average price target of $83.00.

About Cue Biopharma

Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.

Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.